Insights : sector - Osborne Clarke

Life Sciences and Healthcare

Learn more about this sector

Article list

Life Sciences and Healthcare

US-UK deal reshapes pharma trade and pricing for life sciences businesses

The agreement marks a structural shift in trading conditions, pricing and market access for life sciences companies in both markets

30/04/2026

Read time 5m

Regulatory Outlook

Products | UK Regulatory Outlook April 2026

UK and EU regulatory and legal developments affecting general and digital, life science and healthcare, and sustainable products, including the...

30/04/2026

Read time 10m

Life Sciences and Healthcare

EU privacy regulators adopt a single data-processing lawful basis for clinical trials

The EDPB and the EDPS back the proposed European Biotech Act but urge stronger safeguards for health and genetic data

24/04/2026

Read time 5m

Life Sciences and Healthcare

UK clinical trials regulation undergoes its biggest overhaul in 20 years

New framework streamlines approvals and reporting for sponsors while tightening transparency and pharmacovigilance duties

23/04/2026

Read time 6m

Life Sciences and Healthcare

Belgium tightens food and pharma control with new inter-agency protocol

Regulators strengthen oversight of food supplements, specialised nutrition, medicated feed and veterinary medicines

21/04/2026

Read time 7m

Life Sciences and Healthcare

Supplements from lab to label: the compliance checklist

From concept and formulation through ingredient due diligence and safety, novel food assessments, claims and advertising, labelling and post‑market surveillance...

08/04/2026

Read time 4m

Life Sciences and Healthcare

EU overhauls pharmaceutical law with sweeping 2026 reform package

Landmark reform overhauls incentives, supply obligations and regulatory pathways for pharmaceuticals operating in Europe

31/03/2026

Read time 10m

Life Sciences and Healthcare

Nagoya Protocol compliance shapes EU sourcing of genetic resources for R&D

Life sciences, food and cosmetics businesses using biological materials should assess their exposure to ABS obligations

30/03/2026

Read time 7m

Regulatory Outlook

Products | UK Regulatory Outlook March 2026

General/digital products: Consultation on unregulated construction products | Commission consults on draft guidance for the EU Cyber Resilience Act |...

26/03/2026

Read time 13m

Corporate

How American capital pursuing Belgian investment or acquisition targets can mitigate deal‑breaker risks

US funds willing to invest in or acquire Belgian companies face pitfalls – good planning and advisers can drive success

12/03/2026

Read time 6m

Regulatory and compliance

Weighty matters: GLP-1s and the UK regulatory diet they cannot escape

As weight-loss medicines drive rapid shifts in consumer behaviour, food, retail and digital health businesses are racing to respond, with...

12/03/2026

Read time 4m

Life Sciences and Healthcare

EU drug agency proposes permanent clinical trial flexibility framework for crisis times

Expedited approvals, remote monitoring and decentralised elements anchor proposed EU trial rules for emergencies

11/03/2026

Read time 7m

Competition, antitrust and trade

CMA sets out new guidance on collaborations between UK universities and research institutions

The guidance identifies what higher education providers can and cannot do as they look to work more closely together

09/03/2026

Read time 3m

Life Sciences and Healthcare

Italy's Sunshine Act: a system ready but still not operational

Although reporting obligations are not yet in force, operators should prepare for the necessary internal adjustments

04/03/2026

Read time 5m

Regulatory Outlook

Products | UK Regulatory Outlook February 2026

General/digital products: EU product compliance: digitalisation and common specifications proposals | Proposal to amend EU regulations on AI rules Life...

26/02/2026

Read time 18m

View all insights

Life Sciences and Healthcare

US-UK deal reshapes pharma trade and pricing for life sciences businesses

The agreement marks a structural shift in trading conditions, pricing and market access for life sciences companies in both markets

30/04/2026

Read time 5m

Regulatory Outlook

Products | UK Regulatory Outlook April 2026

UK and EU regulatory and legal developments affecting general and digital, life science and healthcare, and sustainable products, including the...

30/04/2026

Read time 10m

Life Sciences and Healthcare

EU privacy regulators adopt a single data-processing lawful basis for clinical trials

The EDPB and the EDPS back the proposed European Biotech Act but urge stronger safeguards for health and genetic data

24/04/2026

Read time 5m

Life Sciences and Healthcare

UK clinical trials regulation undergoes its biggest overhaul in 20 years

New framework streamlines approvals and reporting for sponsors while tightening transparency and pharmacovigilance duties

23/04/2026

Read time 6m

Life Sciences and Healthcare

Belgium tightens food and pharma control with new inter-agency protocol

Regulators strengthen oversight of food supplements, specialised nutrition, medicated feed and veterinary medicines

21/04/2026

Read time 7m

Life Sciences and Healthcare

Supplements from lab to label: the compliance checklist

From concept and formulation through ingredient due diligence and safety, novel food assessments, claims and advertising, labelling and post‑market surveillance...

08/04/2026

Read time 4m

Life Sciences and Healthcare

EU overhauls pharmaceutical law with sweeping 2026 reform package

Landmark reform overhauls incentives, supply obligations and regulatory pathways for pharmaceuticals operating in Europe

31/03/2026

Read time 10m

Life Sciences and Healthcare

Nagoya Protocol compliance shapes EU sourcing of genetic resources for R&D

Life sciences, food and cosmetics businesses using biological materials should assess their exposure to ABS obligations

30/03/2026

Read time 7m

Regulatory Outlook

Products | UK Regulatory Outlook March 2026

General/digital products: Consultation on unregulated construction products | Commission consults on draft guidance for the EU Cyber Resilience Act |...

26/03/2026

Read time 13m

Corporate

How American capital pursuing Belgian investment or acquisition targets can mitigate deal‑breaker risks

US funds willing to invest in or acquire Belgian companies face pitfalls – good planning and advisers can drive success

12/03/2026

Read time 6m

Regulatory and compliance

Weighty matters: GLP-1s and the UK regulatory diet they cannot escape

As weight-loss medicines drive rapid shifts in consumer behaviour, food, retail and digital health businesses are racing to respond, with...

12/03/2026

Read time 4m

Life Sciences and Healthcare

EU drug agency proposes permanent clinical trial flexibility framework for crisis times

Expedited approvals, remote monitoring and decentralised elements anchor proposed EU trial rules for emergencies

11/03/2026

Read time 7m

Competition, antitrust and trade

CMA sets out new guidance on collaborations between UK universities and research institutions

The guidance identifies what higher education providers can and cannot do as they look to work more closely together

09/03/2026

Read time 3m

Life Sciences and Healthcare

Italy's Sunshine Act: a system ready but still not operational

Although reporting obligations are not yet in force, operators should prepare for the necessary internal adjustments

04/03/2026

Read time 5m

Regulatory Outlook

Products | UK Regulatory Outlook February 2026

General/digital products: EU product compliance: digitalisation and common specifications proposals | Proposal to amend EU regulations on AI rules Life...

26/02/2026

Read time 18m

View all insights

Will James

Partner, International Life Sciences and Healthcare Sector Co-Leader

+44 207 105 7774 Email Will Full bio UK

Dr. Andrea Schmoll

Partner, International Life Sciences and Healthcare Sector Co-Leader

+49 221 5108 4408 Email Andrea Full bio Germany

Thomas Devred

Partner, Head of Life Sciences and Healthcare - Paris

+ 33 1 84 82 41 06 Email Thomas Full bio France

Silvia Steiner

Partner

+34 93 419 18 18 Email Silvia Full bio Spain

Maria Grazia Medici

Partner, Head of Life Sciences & Healthcare

+39 06 3269 5015 Email Maria Grazia Full bio Italy

Herke van Hulst

Co-chair of the International Council, Partner, Lawyer

+31 207 02 86 72 Email Herke Full bio The Netherlands

Catherine Wolfenden

Partner, Disputes & Risk Practice Group Head

+44 117 917 3600 Email Catherine Full bio UK

Marcus Vass

Partner, Head of Digital Health

UK +44 2071 057 634 Email Marcus Full bio UK

Rafael García del Poyo

Partner

+34 91 576 44 76 Email Rafael Full bio Spain

Peter Rudd-Clarke

Partner

+44 207 105 7315 Email Peter Full bio UK

Tim Harris

Partner

+44 207 105 7144 Email Tim Full bio UK

Giulia Verusio

Senior Associate

+39 06 3269 5008 Email Giulia Full bio Italy

J. Carlos Suárez

Counsel

+39 02 5413 1772 Email J. Carlos Full bio Italy

David Haex

Co-Managing Partner

+32 2 515 9322 Email David Full bio Belgium

Xavier Pican

Partner, IP/IT/Data

+33 1 84 82 45 88 Email Xavier Full bio France

Julia Kaufmann, LL.M.

Partner

+49 89 5434 8068 Email Julia Full bio Germany

Dr Flemming Moos

Partner, Specialist lawyer for IT law

+49 40 55436 4054 Email Flemming Full bio Germany

Dr Tim Reinhard

Partner, Head of Intellectual Property Germany, Wirtschaftsmediator (MuCDR)

+49 89 5434 8024 Email Tim Full bio Germany

Dr Martin Sundermann

Partner, Wirtschaftsmediator (MuCDR)

+49 89 5434 8026 Email Martin Full bio Germany

Steve Wilson

Managing Partner

+1 917 545 3672 Email Steve Full bio US

Jordi Casas

Co-Managing Partner

+34 93 419 18 18 Email Jordi Full bio Spain

Vladimir Murovec

Counsel, Head of Life Sciences Regulatory

+32 472 607 628 Email Vladimir Full bio Belgium

Hadrien Chef

Partner

+32 2 515 93 24 Email Hadrien Full bio Belgium

View all

Belgium

China

France

Germany

India

Italy

Poland

Singapore

Spain

Sweden

The Netherlands

UK

USA

Insights

Life Sciences and Healthcare

Article list

Connect with one of our experts

Sign up for our newsletter

Legal Notice